Is Adrx a buy?
Ardelyx has received a consensus rating of Buy. The company’s average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Is ARDX a good stock to buy?
Out of 6 analysts, 3 (50%) are recommending ARDX as a Strong Buy, 0 (0%) are recommending ARDX as a Buy, 3 (50%) are recommending ARDX as a Hold, 0 (0%) are recommending ARDX as a Sell, and 0 (0%) are recommending ARDX as a Strong Sell.
Will ardelyx go up?
Ardelyx Inc (NASDAQ:ARDX) The 6 analysts offering 12-month price forecasts for Ardelyx Inc have a median target of 4.00, with a high estimate of 12.00 and a low estimate of 1.00. The median estimate represents a +508.46% increase from the last price of 0.66.
What is going on with ardelyx?
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022.
Why did ARDX stock drop?
ARDX, -9.45% plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s announcement that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients.
Will ARDX get FDA approval?
(NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that the U.S. Food and Drug Administration has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of …
Why is ardelyx down?
The drugmaker’s stock is tanking today in response to a July 13 letter from the U.S. Food and Drug Administration regarding the company’s New Drug Application (NDA) for tenapanor as a treatment for controlling serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Why is ardelyx dropping?
Pharmaceutical company Ardelyx Inc. saw a 70% drop in its stock value on Monday after announcing that the FDA had “identified deficiencies” in the company’s new drug application for its serum phosphorus drug tenapanor.
Is Ibsrela available in the US?
About Ardelyx, Inc. Ardelyx’s first approved product, IBSRELA (tenapanor) is available in the United States.
Will Ardelyx get FDA approval?
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation. FREMONT, Calif. , Sept. 12, 2019 /PRNewswire/ — Ardelyx, Inc.
Is Ibsrela FDA approved?
IBSRELA is the first FDA-approved product for Ardelyx. “The commercialization of IBSRELA marks a significant milestone for Ardelyx and for adult patients with IBS-C and their healthcare providers,” said Mike Raab, president and chief executive officer of Ardelyx.
Who makes Ibsrela?
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation | Ardelyx, Inc.
Is Ibsrela available?
Ibsrela is supplied as 50mg tablets in 60-count bottles. Credit: Ardelyx. Ibsrela® (tenapanor) is now available for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Is Ibsrela available in USA?
Will ardelyx get FDA approval?
What is the newest drug for IBS?
Two new drugs for IBS – rifaximin, an antibiotic, and eluxadoline, an antagonist and agonist of the δ and µ opioid receptors, respectively – have been approved for use in the United States.
What is the best painkiller for IBS?
“I sometimes tell patients to stay away from ibuprofen (like Advil® or Motrin®) and naproxen (like Aleve®) because they can cause stomach discomfort,” says Dr. Tosch. “Over long periods of time, they can cause ulcers. If you need something for pain, Tylenol® (acetaminophen) is the best option.”
https://www.youtube.com/watch?v=KfMtXjLJdu4